Medicaid supplemental rebate agreement

The New York Department of Health has awarded contract X043978 to Actelion Pharmaceuticals US Inc., effective October 1, 2026, through September 30, 2029. The contract represents a three-year period of performance; however, the specific products and services to be delivered are not detailed in the available contract documentation. Based on the awardee's corporate profile as a pharmaceutical manufacturer, the contract likely involves the provision of pharmaceutical products or related services to support state health initiatives, though the precise scope of work, deliverables, and therapeutic areas cannot be definitively determined from the information provided.

The cumulative contract value is currently recorded as $0.00, and neither an annual value nor total contract amount has been specified in the available award documentation. Without access to the detailed statement of work, contract specifications, or performance metrics, the exact nature of services, delivery locations, and financial terms cannot be clarified. Interested parties requiring comprehensive details regarding contract scope, performance requirements, or valuation should consult the official New York State procurement records or contact the Department of Health directly for complete contract documentation.